Loading clinical trials...
Loading clinical trials...
Phase 2, Multi-center, Open-label Trial to Evaluate Efficacy and Safety of GM-CT-01 in Combination With 5-FU as First Line Chemotherapy in Patients With Advanced Biliary Cancer
Conditions
Interventions
GM-CT-01
5-Fluorouracil
Locations
3
United States
Boston Medical Center
Boston, Massachusetts, United States
University of Michigan, Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Barrett Cancer Center
Cincinnati, Ohio, United States
Start Date
September 1, 2006
Primary Completion Date
June 1, 2009
Completion Date
June 1, 2009
Last Updated
August 1, 2017
NCT07146646
NCT06123117
NCT05833815
NCT05404347
NCT05184400
NCT07310069
Lead Sponsor
Galectin Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions